المؤلفون: Puig, Noemi, Hernández, Miguel T, Rosiñol, Laura, González, Esther, de Arriba, Felipe, Oriol, Albert, González-Calle, Verónica, Escalante, Fernando, de la Rubia, Javier, Gironella, Mercedes, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José M, Alegre, Adrián, Martín, Jesús, Gutiérrez, Norma C, Calasanz, María J, Martín, María L, Couto, María Del Carmen, Casanova, María, Arnao, Mario, Pérez-Persona, Ernesto, Garzón, Sebastián, González, Marta S, Martín-Sánchez, Guillermo, Ocio, Enrique M, Coleman, Morton, Encinas, Cristina, Vale, Ana M, Teruel, Ana I, Cortés-Rodríguez, María, Paiva, Bruno, Cedena, M Teresa, San-Miguel, Jesús F, Lahuerta, Juan J, Bladé, Joan, Niesvizky, Ruben, Mateos, María-Victoria

مصطلحات موضوعية: Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Clarithromycin, Dexamethasone, Female, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Male, Multiple Myeloma, Transplantation, Autologous, Treatment Outcome

الوصف: Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or without clarithromycin until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). With a median follow-up of 19 months (range, 0-54), no significant differences in the median PFS were observed between the two arms (C-Rd 23 months, Rd 29 months; HR 0.783, p = 0.14), despite a higher rate of complete response (CR) or better in the C-Rd group (22.6% vs 14.4%, p = 0.048). The most common G3-4 adverse events were neutropenia [12% vs 19%] and infections [30% vs 25%], similar between the two arms; however, the percentage of toxic deaths was higher in the C-Rd group (36/50 [72%] vs 22/40 [55%], p = 0.09). The addition of clarithromycin to Rd in untreated transplant ineligible MM patients does not improve PFS despite increasing the ≥CR rate due to the higher number of toxic deaths in the C-Rd arm. Side effects related to overexposure to steroids due to its delayed clearance induced by clarithromycin in this elderly population could explain these results. The trial was registered in clinicaltrials.gov with the name GEM-CLARIDEX: Ld vs BiRd and with the following identifier NCT02575144. The full trial protocol can be accessed from ClinicalTrials.gov. This study received financial support from BMS/Celgene.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/17818Test; PMC8139975; https://www.nature.com/articles/s41408-021-00490-8.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139975/pdfTest

الإتاحة: https://doi.org/10.1038/s41408-021-00490-8Test
http://hdl.handle.net/10668/17818Test
https://www.nature.com/articles/s41408-021-00490-8.pdfTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139975/pdfTest

المؤلفون: Paiva, Bruno, Puig, Noemi, Cedena, Maria-Teresa, Rosiñol, Laura, Cordón, Lourdes, Vidriales, María-Belén, Burgos, Leire, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Lopez-Anglada, Lucia, Maldonado, Roberto, de la Cruz, Javier, Gutierrez, Norma C, Calasanz, Maria-Jose, Martin-Ramos, Maria-Luisa, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Blanchard, María-Jesús, Rios, Rafael, Martin, Jesus, Martinez-Martinez, Rafael, Sureda, Anna, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Van Dongen, Jacques J M, Orfao, Alberto, Mateos, Maria-Victoria, Blade, Joan, San-Miguel, Jesús F, Lahuerta, Juan-José, GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group

مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Clinical Trials, Phase III as Topic, Dexamethasone, Female, Flow Cytometry, Humans, Lenalidomide, Longitudinal Studies, Male, Middle Aged, Multiple Myeloma, Neoplasm, Residual, Randomized Controlled Trials as Topic

الوصف: Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1,100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial. Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM.

العلاقة: http://hdl.handle.net/10668/14743Test

الإتاحة: https://doi.org/10.1200/JCO.19.01231Test
http://hdl.handle.net/10668/14743Test

المؤلفون: Lahuerta, Juan-José, Jiménez-Ubieto, Ana, Paiva, Bruno, Martínez-López, Joaquín, González-Medina, José, López-Anglada, Lucía, Cedena, María-Teresa, Puig, Noemi, Oriol, Albert, Blanchard, María-Jesús, Ríos, Rafael, Martin, Jesús, Martínez, Rafael, Sureda, Anna, Hernández, Miguel Teodoro, de la Rubia, Javier, Krsnik, Isabel, Cabañas, Valentín, Palomera, Luis, Bargay, Joan, Mateos, María-Victoria, Rosiñol, Laura, San Miguel, Jesús F, Blade, Joan

مصطلحات موضوعية: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Electrophoresis, Female, Humans, Male, Middle Aged, Multiple Myeloma, Myeloma Proteins, Randomized Controlled Trials as Topic, Treatment Outcome

الوصف: Response criteria for multiple myeloma (MM) require monoclonal protein (M-protein)-negative status on both serum immunofixation electrophoresis (sIFE) and urine (uIFE) immunofixation electrophoresis for classification of complete response (CR). However, uIFE is not always performed for sIFE-negative patients. We analyzed M-protein evaluations from 384 MM patients (excluding those with light-chain-only disease) treated in the GEM2012MENOS65 (NCT01916252) trial to determine the uIFE-positive rate in patients who became sIFE-negative posttreatment and evaluate rates of minimal residual disease (MRD)-negative status and progression-free survival (PFS) among patients achieving CR, CR but without uIFE available (uncertain CR; uCR), or very good partial response (VGPR). Among 107 patients with M-protein exclusively in serum at diagnosis who became sIFE-negative posttreatment and who had uIFE available, the uIFE-positive rate was 0%. Among 161 patients with M-protein in both serum and urine at diagnosis who became sIFE-negative posttreatment, 3 (1.8%) were uIFE positive. Among patients achieving CR vs uCR, there were no significant differences in postconsolidation MRD-negative (

العلاقة: http://hdl.handle.net/10668/13863Test; https://ashpublications.org/blood/article-pdf/133/25/2664/1557496/bloodbld2019000671.pdfTest

الإتاحة: https://doi.org/10.1182/blood.2019000671Test
http://hdl.handle.net/10668/13863Test
https://ashpublications.org/blood/article-pdf/133/25/2664/1557496/bloodbld2019000671.pdfTest

المؤلفون: Mateos Manteca, María Victoria, Hernández, José M., Hernández, Miguel T., Gutiérrez Gutiérrez, Norma Carmen, Palomera, Luis, Fuertes, M., Díaz-Mediavilla, Joaquín, Lahuerta, Juan José, De la Rubia, Javier, Terol, María-José, Sureda, Anna, Bargay, Joan, Ribas, Paz, De Arriba, Felipe, Alegre, Adrian, Oriol, Albert, Carrera, Dolores, García-Laraña, José, García Sanz, Ramón, Bladé, Joan, Prósper, Felipe, Mateo, Gemma, Esseltine, Dixie-Lee, van de Velde, Helgi, San Miguel Izquierdo, Jesús Fernando

مصطلحات موضوعية: Mieloma múltiple, Disease-Free Survival, Immunophenotyping, Aged, Boronic Acids, Humans, Pyrazines, Melphalan, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Multiple Myeloma, Maximum Tolerated Dose, Cohort Studies, Prednisone, protocolos de quimioterapia antineoplásica combinada, humanos, anciano, supervivencia sin enfermedad, prednisona, inmunofenotipificación, ácidos borónicos, dosis máxima tolerada, estudios de cohortes, antineoplásicos, piracinas, melfalán

الوصف: [EN]Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP). However, complete responses (CRs) are rare. Bortezomib is active in patients with relapsed MM, including elderly patients. This phase 1/2 trial in 60 untreated MM patients aged at least 65 years (half older than 75 years) was designed to determine dosing, safety, and efficacy of bortezomib plus MP (VMP). VMP response rate was 89%, including 32% immunofixation-negative CRs, of whom half of the IF- CR patients analyzed achieved immunophenotypic remission (no detectable plasma cells at 10(-4) to 10(-5) sensitivity). VMP appeared to overcome the poor prognosis conferred by retinoblastoma gene deletion and IgH translocations. Results compare favorably with our historical control data for MP--notably, response rate (89% versus 42%), event-free survival at 16 months (83% versus 51%), and survival at 16 months (90% versus 62%). Side effects were predictable and manageable; principal toxicities were hematologic, gastrointestinal, and peripheral neuropathy and were more evident during early cycles and in patients aged 75 years or more. In conclusion, in elderly patients ineligible for transplantation, the combination of bortezomib plus MP appears significantly superior to MP, producing very high CR rates, including immunophenotypic CRs, even in patients with poor prognostic features.

العلاقة: https://doi.org/10.1182/blood-2006-04-019778Test; Mateos, M. V., Hernández, J. M., Hernández, M. T., Gutiérrez, N. C., Palomera, L., Fuertes, M., . & Miguel, J. F. S. (2006). Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 108(7), 2165-2172. https://doi.org/10.1182/blood-2006-04-019778Test; http://hdl.handle.net/10366/154234Test

الإتاحة: https://doi.org/10.1182/blood-2006-04-019778Test
http://hdl.handle.net/10366/154234Test

المؤلفون: Lonial, Sagar, Weiss, Brendan M, Usmani, Saad Z, Singhal, Seema, Chari, Ajai, Bahlis, Nizar J, Belch, Andrew, Krishnan, Amrita, Vescio, Robert A, Mateos, Maria Victoria, Mazumder, Amitabha, Orlowski, Robert Z, Sutherland, Heather J, Bladé, Joan, Scott, Emma C, Oriol, Albert, Berdeja, Jesus, Gharibo, Mecide, Stevens, Don A, Leblanc, Richard, Sebag, Michael, Callander, Natalie, Jakubowiak, Andrzej, White, Darrell, De La Rubia, Javier, Richardson, Paul G., Lisby, Steen, Feng, Huaibao, Uhlar, Clarissa M, Khan, Imran, Ahmadi, Tahamtan, Voorhees, Peter M

المصدر: The Lancet, 387(10027)

مصطلحات موضوعية: Kaplan-Meier Estimate, Male, Antineoplastic Agents, Antibodies, Monoclonal, Spain, Middle Aged, Disease-Free Survival, United States, Antineoplastic Combined Chemotherapy Protocols, daratumumab, Female, Drug Administration Schedule, Aged, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local, Multiple Myeloma, Canada, Treatment Outcome, Humans, Adult

الوصف: BACKGROUND: New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs. We assessed daratumumab, a novel CD38-targeted monoclonal antibody, in patients with refractory multiple myeloma. METHODS: In this open-label, multicentre, phase 2 trial done in Canada, Spain, and the USA, patients (age ≥18 years) with multiple myeloma who were previously treated with at least three lines of therapy (including proteasome inhibitors and immunomodulatory drugs), or were refractory to both proteasome inhibitors and immunomodulatory drugs, were randomly allocated in a 1:1 ratio to receive intravenous daratumumab 8 mg/kg or 16 mg/kg in part 1 stage 1 of the study, to decide the dose for further assessment in part 2. Patients received 8 mg/kg every 4 weeks, or 16 mg/kg per week for 8 weeks (cycles 1 and 2), then every 2 weeks for 16 weeks (cycles 3-6), and then every 4 weeks thereafter (cycle 7 and higher). The allocation schedule was computer-generated and randomisation, with permuted blocks, was done centrally with an interactive web response system. In part 1 stage 2 and part 2, patients received 16 mg/kg dosed as in part 1 stage 1. The primary endpoint was overall response rate (partial response [PR] + very good PR + complete response [CR] + stringent CR). All patients who received at least one dose of daratumumab were included in the analysis. The trial is registered with ClinicalTrials.gov, number NCT01985126. FINDINGS: The study is ongoing. In part 1 stage 1 of the study, 18 patients were randomly allocated to the 8 mg/kg group and 16 to the 16 mg/kg group. Findings are reported for the 106 patients who received daratumumab 16 mg/kg in parts 1 and 2. Patients received a median of five previous lines of therapy (range 2-14). 85 (80%) patients had previously received autologous stem cell transplantation, 101 (95%) were refractory to the most recent proteasome inhibitors and immunomodulatory drugs used, and 103 (97%) were refractory to the last ...

العلاقة: https://doi.org/10.17615/c9e2-m654Test; https://cdr.lib.unc.edu/downloads/xs55mj293?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/xs55mj293Test

الإتاحة: https://doi.org/10.17615/c9e2-m654Test
https://cdr.lib.unc.edu/downloads/xs55mj293?file=thumbnailTest
https://cdr.lib.unc.edu/downloads/xs55mj293Test

المؤلفون: Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervã©, Hulin, Cyrille, Facon, Thierry, Petrini, Mario

المساهمون: Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, Dührsen, Ulrich (Beitragende*r)

المصدر: NEW ENGLAND JOURNAL OF MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

مصطلحات موضوعية: Melphalan, Oncology, Adult, Male, medicine.medical_specialty, Medizin, Kaplan-Meier Estimate, Dexamethasone, Disease-Free Survival, Ixazomib, chemistry.chemical_compound, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Medicine (all), Internal medicine, medicine, 80 and over, Multiple myeloma, Lenalidomide, Antineoplastic Combined Chemotherapy Protocol, business.industry, Hazard ratio, General Medicine, medicine.disease, Surgery, Transplantation, chemistry, business, Human, medicine.drug

الوصف: BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab6a250a554f78e8e5a90914b31416a7Test
http://hdl.handle.net/11568/884323Test

المؤلفون: Mateos Manteca, María Victoria, Hernández, Miguel-Teodoro, Giraldo, Pilar, De la Rubia, Javier, De Arriba, Felipe, López Corral, Lucía, Rosiñol, Laura, Paiva, Bruno, Palomera, Luis, Bargay, Joan, Oriol, Albert, Prósper, Felipe, López, Javier, Olavarría, Eduardo, Quintana, Nuria, García, José-Luis, Bladé, Joan, Lahuerta, Juan José, San Miguel Izquierdo, Jesús Fernando

مصطلحات موضوعية: Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Disease Progression, Female, Follow-Up Studies, Humans, Induction Chemotherapy, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Risk, Survival Rate, Thalidomide, talidomida, protocolos de quimioterapia antineoplásica combinada, dexametasona, humanos, anciano, estudios de seguimiento, mediana edad, mieloma múltiple, riesgo, tasa de supervivencia, quimioterapia de inducción, adulto, progresión de la enfermedad

الوصف: [EN]For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. In this randomized, open-label, phase 3 trial, we randomly assigned 119 patients with high-risk smoldering myeloma to treatment or observation. Patients in the treatment group received an induction regimen (lenalidomide at a dose of 25 mg per day on days 1 to 21, plus dexamethasone at a dose of 20 mg per day on days 1 to 4 and days 12 to 15, at 4-week intervals for nine cycles), followed by a maintenance regimen (lenalidomide at a dose of 10 mg per day on days 1 to 21 of each 28-day cycle for 2 years). The primary end point was time to progression to symptomatic disease. Secondary end points were response rate, overall survival, and safety. After a median follow-up of 40 months, the median time to progression was significantly longer in the treatment group than in the observation group (median not reached vs. 21 months; hazard ratio for progression, 0.18; 95% confidence interval [CI], 0.09 to 0.32; P<0.001). The 3-year survival rate was also higher in the treatment group (94% vs. 80%; hazard ratio for death, 0.31; 95% CI, 0.10 to 0.91; P=0.03). A partial response or better was achieved in 79% of patients in the treatment group after the induction phase and in 90% during the maintenance phase. Toxic effects were mainly grade 2 or lower. Early treatment for patients with high-risk smoldering myeloma delays progression to active disease and increases overall survival. (Funded by Celgene; ClinicalTrials.gov number, NCT00480363.).

العلاقة: Mateos, M. V., Hernández, M. T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., . & San Miguel, J. F. (2013). Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. New England Journal of Medicine, 369(5), 438-447. doi:10.1056/NEJMoa1300439. PMID: 23902483.; http://hdl.handle.net/10366/154298Test

الإتاحة: https://doi.org/10.1056/NEJMoa1300439Test
http://hdl.handle.net/10366/154298Test

المؤلفون: Lahuerta, Juan José, Mateos Manteca, María Victoria, Martínez-López, Joaquin, Rosiñol, Laura, Sureda, Anna, De la Rubia, Javier, García-Laraña, José, Martínez-Martínez, Rafael, Hernández-García, Miguel T., Carrera, Dolores, Besalduch, Joan, De Arriba, Felipe, Ribera, José-María, Escoda, Lourdes, Hernández-Ruiz, Belén, García-Frade, Javier, Rivas-González, Concepción, Alegre, Adrian, Bladé, Joan, San Miguel Izquierdo, Jesús Fernando

مصطلحات موضوعية: Mieloma múltiple, Disease-Free Survival, Transplantation, Aged, Kaplan-Meier Estimate, Transplantation Conditioning, Adult, Humans, Antineoplastic Combined Chemotherapy Protocols, Middle Aged, Multiple Myeloma, Prospective Studies, Time Factors, Stem Cell Transplantation, Treatment Outcome, Remission Induction, protocolos de quimioterapia antineoplásica combinada, trasplante de células madre, humanos, inducción de remisión, factores de tiempo, anciano, trasplante, mediana edad, supervivencia sin enfermedad, estudios prospectivos, adulto, acondicionamiento para el trasplante, resultado del tratamiento, estimación de Kaplan-Meier

الوصف: [EN]Complete response (CR) is considered an important goal in most hematologic malignancies. However, in multiple myeloma (MM), there is no consensus regarding whether immunofixation (IF)-negative CR, IF-positive near-CR (nCR), and partial response (PR) are associated with different survivals. We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM. We analyzed 632 patients from the prospective Grupo Español de Mieloma 2000 protocol who were uniformly treated with vincristine, carmustine, cyclophosphamide, melphalan, and predisone/vincristine, carmustine, adryamcine, and dexamethasone induction followed by high-dose therapy and autologous stem-cell transplantation. Post-transplantation response markedly influenced outcomes. Patients achieving CR had significantly longer EFS (median, 61 v 40 months; P < 10(-5)) and OS (medians not reached; P = .01) versus patients achieving nCR, who likewise had somewhat better outcomes compared with patients achieving PR (median EFS, 34 months, P = .07 v nCR; median OS, 61 months, P = .04). EFS and OS and influence of response were similar among older (age 65 to 70 years) and younger (age < 65 years) patients. Similar findings were observed with pretransplantation response, with trends toward EFS (P = .1; P = .05) and OS (P = .1; P = .07) benefit in patients achieving CR versus nCR and PR, respectively. Post-transplantation response was markedly influenced by pretransplantation response; improvements in response were associated with prolonged survival. Quality of response post-transplantation, notably CR, is significantly associated with EFS and OS prolongation in newly diagnosed patients with MM. There were trends toward similar associations with pretransplantation response status.

العلاقة: https://doi.org/10.1200/JCO.2008.17.9721Test; Lahuerta, J. J., Mateos, M. V., Martínez-López, J., Rosinol, L., Sureda, A., de la Rubia, J., . & San Miguel, J. F. (2008). Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. Journal of Clinical Oncology, 26(35), 5775-5782. doi:10.1200/JCO.2008.17.9721. Epub 2008 Nov 10. PMID: 19001321.; http://hdl.handle.net/10366/154330Test

الإتاحة: https://doi.org/10.1200/JCO.2008.17.9721Test
http://hdl.handle.net/10366/154330Test